Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The efficacy of indomethacin, a prostaglandin synthetase inhibitor, in severe dysmenorrhoea was established in a double-blind crossover study using aspirin and placebo as the control drugs. Forty-seven female undergraduates were treated twice with each of the three substances during six consecutive menstrual cycles. Good or moderate relief was achieved in 71% of the cycles treated with indomethacin, in 40% of those treated with aspirin and in 21% of those treated with the placebo. Dizziness and drowsiness were cited by 14 patients (30%) as side-effects of indomethacin, none of these patients discontinued the therapy because all obtained good or moderate relief from dysmenorrhoea. Indomethacin proved to be a valuable agent, and significantly better than aspirin in the treatment of dysmenorrhoea. It allowed many dysmenorrhoeic women to carry out their normal activities and work during the menstrual period.
 ...
PMID:Indomethacin in the treatment of primary dysmenorrhoea. 34 93

The efficacy of indomethacin suppositories (100 mg 1-3 times a day) in the treatment of primary dysmenorrhoea was investigated in a double-blind, crossover study involving 40 patients, in comparison to placebo. The patients were treated for four menstrual periods-two periods with placebo and two periods with indomethacin suppositories. A dysmenorrhoeic score based on subjective estimations of nine symptoms was used, the symptoms including pelvic pain, backache, headache, dizziness, nausea, vomiting, diarrhoea, nervousness and incapacitation. As compared to placebo, indomethacin suppositories led to a insignificant decrease in the frequency and severity of the associated symptoms, as evaluated by subjective rating (P less than 0.05). Indomethacin suppositories were well tolerated and there was no drop-out. No side effects were reported except for a mild burning sensation in the rectal region experienced by 3 patients on indomethacin suppositories.
 ...
PMID:Efficacy of indomethacin suppository in primary dysmenorrhoea. 222 77

In a controlled crossover study healthy volunteers received a single oral dose of 75 mg indomethacin, 75 mg sustained-release indomethacin, or the new therapeutic system indomethacin Gits 7/85. Dependence on the time of administration was investigated by comparing the plasma level curves obtained following morning and evening administration of indomethacin and indomethacin Gits. Blood samples were taken at defined intervals following administration for determination of indomethacin plasma levels. To determine urinary excretion of prostaglandin (PG)E2, urine was collected during four consecutive 6 h-clearance periods after administration of the indomethacin preparations. The plasma level curve following administration of indomethacin Gits 7/85 did not exhibit clearly distinct initial peaks and, in contrast to the other drug preparations, remained nearly constant over 10-12 h. Indomethacin induced a significant suppression of urinary PGE2 excretion over a period of 12 h, whereas both sustained release indomethacin and indomethacin Gits 7/85 decreased urinary PGE2 excretion for 18 h. Neither the plasma concentration curve of indomethacin nor the inhibitory effect on urinary PGE2 excretion was dependent on the time of administration. Initial central nervous side effects, such as dizziness, were reported by all volunteers after taking indomethacin and by half of the volunteers following sustained release indomethacin, whereas no adverse effects were observed after administration of indomethacin Gits 7/85. The present study demonstrates that indomethacin Gits 7/85 produces no initial peaks of plasma levels but rather a sustained concentration plateau. The excellent tolerability of indomethacin Gits 7/85 is probably due to the lack of peak plasma concentrations.
 ...
PMID:[Indomethacin kinetics and urinary excretion of prostaglandin E2 following oral administration of various dosage forms of indomethacin]. 658 Jul 89

Twelve rheumatic patients were given 2.0 and 4.5 g acetylsalicylic acid daily in two 3-week periods. On days 13 and 20 of each period the patients took a suppository containing either placebo or 50 mg of indomethacin. The study was performed double-blind. Indomethacin had a significant additive effect during ASA therapy with 2 g daily as estimated by articular index and subjective ratings of pain and morning stiffness. On the 4.5 g ASA dose there was a significant improvement only for articular index. The patients experienced less pain during maintenance therapy with 4.5 g of ASA compared with 2.0 g daily. Both ASA doses induced complete inhibition of prostaglandin PGF2 alpha release from platelets. Thus the suppression of PGF2 alpha release does not reflect the therapeutic response of these drugs. Side effects observed comprised tinnitus, dizziness and gastritis. In 2 of the patients the aminotransferase levels increased, indicating hepatotoxicity. The protein binding of salicylate decreased with increasing salicylate concentration. As the dose was increased from 2.0 to 4.5 g/day the unbound concentration increased 5 to 24 times. This reflects the combined effect of capacity-limited metabolism and capacity-limited protein binding of salicylate.
 ...
PMID:Additive clinical effect of indomethacin suppositories during salicylate therapy in rheumatoid patients. 701 17

The CSF-pressure-lowering effects of indomethacin in seven patients with idiopathic intracranial hypertension and one patient with symptomatic intracranial hypertension due to a non-space-occupying meningioma are reported. CSF opening pressure between 350 and 500 mm H2O (mean 400 mm H2O) was promptly reduced by 80 to 200 mm H2O (mean reduction, 139 mm H2O) for at least 10 minutes in all patients after IV administration of 50 mg indomethacin. Four patients had mild and transient side effects (dizziness). Indomethacin might be an alternative drug for treatment of intracranial hypertension.
 ...
PMID:Indomethacin reduces CSF pressure in intracranial hypertension. 1106 Dec 68